FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010

•French real world study reviewed first-line extensive-stage SCLC patient data from national real world data cohort.•Participating non-academic hospitals mainly used standard-of-care platinum and etoposide chemotherapy.•Patients receiving cisplatin + etoposide were younger and fitter than those receiving carboplatin + etoposide.•Median OS of chemotherapy-treated first-line extensive-stage SCLC patients varied from 7 to 10 months.•Patients treated with cisplatin + etoposide showed better OS and 1 year survival rates.